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1. Introduction 
Prehospital emergency care personnel can play a crucial role in the identification and 
management of patients presenting with ST Elevation Myocardial Infarction (STEMI). 
Specifically, prehospital thrombolysis by emergency medical personnel such as 
paramedics/nurses/prehospital doctors has been identified as being a successful and safe 
approach for the provision of accelerating reperfusion strategies for acute STEMI. Moreover, 
prehospital thrombolysis has no added specific risks (arguably, it is safer as delayed 
thrombolysis increases the risk of myocardial rupture) as compared to inhospital 
thrombolysis; nor is it an obstacle for later percutaneous coronary intervention (PCI). This 
chapter will focus on the general management of STEMI, the potential benefits related to 
prehospital thrombolysis and alternative, adjunctive therapies and provide some useful 
hints to drug administration. 
Prehospital thrombolysis is an established emergency treatment and has been classified as a 
Class IIa recommendation therapy for acute STEMI by the leading international cardiology 
societies like European Society of Cardiology (2008). Prehospital thrombolysis research is 
ongoing with a large multi-center trial currently recruiting patients in 112 locations 
worldwide – STREAM – Strategic Reperfusion Early After Myocardial Infarction. STREAM 
aims to evaluate, in a proof of concept approach, the outcome of prehospital patients 
presenting with acute STEMI within 3 hours of symptom onset. Following randomization, a 
treatment strategy of early (prehospital) tenecteplase and additional antiplatelet and 
antithrombin therapy followed by catheterization within 6-24 hours with timely coronary 
intervention as appropriate (or by rescue coronary intervention if required) compared to 
primary angioplasty. This intention to treat study will therefore place patients into two 
groups; Group A will receive primary PCI performed according to local standards and 
Group B will receive prehospital thrombolysis supported by optimal supportive adjunctive 
therapy (http://clinical trials.gov.show/NCT00623623). 
2. Development of prehospital thrombolysis 
The first published study of prehospital thrombolysis involved the intravenous 
administration of 750,000 units of streptokinase by physicians was undertaken in 1985. This 
study demonstrated that patients treated less than 1.5 hours after the onset of pain had a 
significantly higher ejection fraction (56±15 vs. 47±14 %; P<0.05), improved infarct-related 
regional ejection fraction (51±19 vs. 34±20 %; P<0.01) and a lower QRS score (5.6±4.9 vs. 
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8.6±5.5; P<0.01) than patients receiving treatment between 1.5 and 4 hours from the onset of 
pain. Patients in the prehospital arm of the study also had better-preserved left ventricular 
function than patients treated in the hospital. The study concluded that thrombolytic 
therapy with streptokinase is most effective when administered within 1.5 hours from onset 
of symptoms of acute myocardial infarction. Although this study produced positive results 
it lacked statistical power (due to small sample size) but it served to highlight the 
importance of timely thrombolysis (Koren et al., 1985). 
Arguably, the Grampian Region Early Anistreplase Trial (GREAT) was the most influential 
prehospital thrombolysis based study. The aim of GREAT was to determine the time saved 
by thrombolysis when initiated at home by trained general practitioners (GPs) / family 
physicians as compared to thrombolysis inhospital. The GPs randomly assigned 
thrombolytic therapy to 311 patients with suspected acute myocardial infarction into two 
groups; prehospital thrombolysis and thrombolysis after arrival at the hospital. GPs selected 
patients on the basis of a history of chest pain from 20 minutes to 4 hours with treatment 
initiated within 6 hours from onset of pain. Patients in the prehospital treatment group 
received thrombolysis up to 130 minutes earlier than patients at hospital (101 vs 240 minutes 
from the onset of symptoms) with a 50% reduction in mortality in the prehospital group; 17 
(10.4%) vs 32 (21.6%). The greatest saving of time was seen in the rural environment as well 
as in areas where there were significant inhospital treatment delays (Rawles, 1994). 
Importantly, during the GREAT study, prehospital thrombolysis was undertaken using a 
single bolus thrombolytic agent.  
Patients enrolled in the GREAT study were followed up at five years where investigators 
noted 25% of the prehospital treatment group had died compared to 36% in the inhospital 
treatment group (Rawles, 1997). The GREAT study reconfirmed the negative impact of time 
delays by demonstrating that delaying thrombolysis by one hour increased the hazard ratio 
of death by 20%, with the equivalent loss of 43 lives per 1000 patients treated at five years. In 
a subset analysis of GREAT patients who met current ECG criteria for thrombolysis 
undertaken  after 10 years, a 16% difference in mortality was maintained between the two 
groups (Rawles, 2003). The benefits seen in GREAT were significantly higher than those 
seen in any other thrombolysis study. The long-term mortality patterns has not been 
replicated in other long-term (inhospital) follow up studies, like ISIS-2 (1988) or GUSTO-1 
(1993).  
Treatment delays and the potential time savings of prehospital thrombolysis are key factors 
in the decision-making process around reperfusion with a meta-analysis by Morrison et al. 
(2000) of six randomized controlled trials clearly demonstrating the impact of the time 
savings to be achieved with prehospital treatment over inhospital treatment. Morrison et al. 
reported on all-cause hospital mortality as well as symptom to treatment time and adverse 
events. Although individual trials failed to demonstrate a statistically significant difference 
in all cause inhospital mortality; the meta-analysis involving 6434 patients showed a pooled 
benefit with prehospital thrombolysis. Morrison et al. demonstrated that prehospital 
thrombolysis saved approximately 60 minutes (p = 0.07) per patient compared to inhospital 
thrombolysis (104 versus 162 minutes) thereby reducing all-cause hospital mortality by 17%. 
If we consider the data from the five year follow up of the GREAT study, such time-savings 
can be extrapolated into significant numbers of lives saved.  
Bjorklund et al. (2006) evaluated treatment delays and outcome in a large cohort of acute 
STEMI patients transported by ambulance who were either thrombolysed by paramedics in 
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the prehospital environment or thrombolysed inhospital. Importantly, Björklund et al. 
utilized data from the Swedish / Register of Cardiac Intensive Care drawing data from 75 
hospitals. Although register based data lacks the scientific controls seen within clinical trials, 
it is arguably more reflective of ‘real life’ clinical care. Following this study, Bjorklund et al. 
were able to conclude that prehospital thrombolysis by paramedics in ambulances was 
associated with reduced time to thrombolysis by almost 1 hour and reduced adjusted 1-year 
mortality by 30%. 
Minimizing treatment delays in the administration of thrombolysis is key to optimizing 
patient outcomes. Although the LATE study (Becker, 1995) demonstrated clinical benefits of 
thrombolysis up to 12 hours, the greatest benefits were seen within 6 hours with the highest 
mortality reduction  seen in those patients treated within the first 3 hours from onset of 
symptoms. The most commonly perceived post thrombolysis risks of stroke or major 
haemorrhage remain static regardless of when within the 12 hour period thrombolytic 
therapy is administered. However, the typically lethal complication of myocardial rupture 
exponentially increases after six hours. As demonstrated in the GREAT, WEST (Armstrong, 
2006) and CAPTIM (Bonnefoy et al., 2009) studies prehospital thrombolysis is more likely to 
recruit patients within the first 6 hours of symptom onset; typically within the first 3 hours 
were the clinical benefit of treatment is at its highest. 
These trails and others help to confirm the feasibility and safety of prehospital thrombolysis 
in a wide variety of circumstances and settings ranging from traditional ambulance services 
through to use by ship-based medical teams (cruise ships) and deployed military medicine. 
However, the choice between reperfusion strategies to manage acute STEMI remains a topic 
of interest. While it is agreed that primary PCI is the best strategy for acute STEMI it is still 
time sensitive and therefore needs to be performed in a timely manner and by experienced 
centres. This is not always achievable in developing countries, in rural health care settings or 
in remote medical facilities such as cruise ships. 
3. Prehospital thrombolysis supported by early intervention 
A number of mixed strategies for reperfusion have been studied; to include prehospital 
thrombolysis (full dose thrombolytic therapy) supported by rescue PCI for failed 
thrombolytic reperfusion (a hybrid reperfusion strategy) plus pre-discharge or 
symptom/ischaemia driven PCI, reduced dose thrombolysis supported by immediate PCI 
(facilitated PCI) and primary PCI. The ASSENT-4 PCI (2006) study demonstrated that 
facilitated thrombolysis, that is,  thrombolysis immediately followed by PCI has been 
proven to be an unsuccessful intervention and will not be discussed further. 
A hybrid reperfusion service involves implementing the best combination of reperfusion 
options to meet the unique requirements of the patient and typically involves early 
prehospital thrombolysis for those patients with the greatest benefit e.g. anterior STEMI 
presenting within 2-3 hours supported by rescue PCI and pre-discharge angioplasty with a 
system of primary PCI for the remaining patients. It must be re-iterated that primary PCI 
does still offer a superior treatment option when it is available in a timely manner.  
The WEST trial investigated the use of a number of different reperfusion strategies, 
immediate prehospital thrombolysis plus usual inhospital care (excluding routine PCI), 
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prehospital thrombolysis with compulsory rescue PCI for failed thrombolysis against 
primary PCI strategy. A key finding of the WEST study was a lower incidence of 
cardiogenic shock in patients who received thrombolysis early (within 3 hours) and the 
importance of prehospital triage/decisions for reperfusion with delays to definitive 
treatment being shorter when a decision was made in the prehospital setting. The WEST 
study also highlighted that thrombolysis used timeously remains an important treatment 
modality in the early management of acute STEMI.  
The larger CAPTIM study used a similar design to the WEST study utilizing prehospital 
triage/decision to prehospital thrombolysis (this time supported by compulsory rescue PCI) 
with pre-discharge coronary intervention compared to primary PCI. The long term 5 year 
follow up of the CAPTIM study confirmed a significant reduction in mortality when 
thrombolysis was administered within 2 hours in the prehospital group when compared 
with primary angioplasty. The relationship between reperfusion strategy and the time from 
symptom onset on 1 year mortality was examined in a pooled analysis of patients from the 
CAPTIM and WEST studies. Mortality benefit was observed time (< 2 hours) (2.8%  vs 6.9%, 
p = 0.021, hazard ratio 0.43, 95% CI 0.20-0.91) emphasizing that time from symptom onset 
was a key determinant when selecting the reperfusion strategy for acute STEMI (Westerhout 
et al., 2011). The optimal design of a hybrid reperfusion service is yet to be determined but 
the data from WEST and CAPTIM would support prehospital thrombolysis within the first 
3 hours as along as all patients were delivered to a receiving hospital with interventional 
cardiology capability. 
Prehospital thrombolysis can clearly be initiated earlier that inhospital thrombolysis or 
primary PCI and it can be performed with limited equipment. In fact, the same minimum 
equipment is required to perform prehospital thrombolysis as is required to identify 
prehospital patients requiring direct admission for primary PCI. Data from WEST 
(paramedic decision-makers), CAPTIM (doctor decision-makers) and projected findings 
from STREAM (paramedic/nurse/doctor decision-makers) are intended to inform the 
debate as to whether a hybrid reperfusion system is appropriate within developed 
countries. Regardless of the reperfusion strategy put into place, empowering the prehospital 
clinician is pivotal to success.  
4. Education, training & equipment 
The efficacy and safety of pre-hospital thrombolysis is dependent on several pre-requisites 
(Birkhead, 2004; Björklund et al., 2006; Mehta et al., 2002; Weaver, 1997; Welsh et al.,  
2006): 
1. Prehospital personnel being trained to recognize symptoms and management of STEMI 
and its early complications (pain, ventricular fibrillation/ventricular tachycardia and 
bradycardic arrhythmias).  
2. Diagnoses of STEMI using a 12 lead ECG with or without computer assistance for 
diagnosis and/or data transmission. 
3. Intravenous access to be established and the administration of reperfusion therapy to be 
initiated within a treatment protocol / clinical guideline and supported by a 
thrombolysis checklist. 
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4. During transportation rhythm monitoring, availability of a defibrillator and advanced 
cardiac life support are mandatory 
5. Pre-alerting receiving hospital of impending arrival of the patient supported by (if 
available) electronic transmission of the 12 lead ECG  
6. Consultation for on-line support can support decision-making  
7. On-going quality assurance 
4.1 Education and training 
The foundation for the practice of thrombolysis requires an understanding of anatomy and 
physiology of cardiovascular system and the pathophysiology of acute coronary syndromes. 
The complications of acute coronary syndromes / acute myocardial infarction must be 
covered as this will prepare the paramedic/nurse/prehospital doctor for complications that 
may arise during clinical practice. The ability to analyze a 12 lead ECG with a particular 
focus on recognition of AMI is required along with an understanding of thrombolytic 
therapy. An evidence based thrombolysis protocol which is subject to regular review is 
required taking into consideration the operational requirements for the practical 
implementation of the protocol. Classroom practice through the use of simulated clinical 
patient scenarios for stable angina, unstable angina, infarctions of the various territories 
including right ventricular infarction and scenarios where thrombolysis is contra-indicated 
will prepare and improve clinical practice. This theoretical and practical classroom 
education and training will need to be supported by clinical exposure within coronary care 
units and cardiac catheterization facilities. 
4.2 Diagnosing acute STEMI 
Van’t Hof et al. (2006) demonstrated that prehospital diagnoses, triage and treatment in the 
ambulance is feasible in 95% of acute STEMI patients when undertaken by highly trained 
paramedics using a validated computerized ECG software. Prehospital decision-making can 
also be improved with the electronic transmission of an ECG although systems that support 
autonomous prehospital thrombolysis are well established and electronic data transmission 
can be problematic as they tend to rely on mobile telephone technology. The availability of 
prehospital 12 lead ECG capabilities serves to improve cardiac care in general and increased 
use of recording and subsequent interpretation of the 12 lead ECGs by prehospital clinicians 
improves overall confidence in using the prehospital ECG as a diagnostic tool. A 
particularly important aspect of the prehospital 12 lead ECG is that it is often obtained in the 
early phase of the patient’s illness and becomes a useful ECG to compare against ECGs 
obtained later on in the patient’s care.  
The availability of diagnostic software and more importantly data transmission introduces 
an interesting concept for remote medical management of STEMI as the formal diagnosis of 
STEMI can be made by a distant clinician with the attending clinician acting primarily as a 
technician. This would involve the practical skills of cannulation, obtaining a 12 lead ECG 
and resuscitation skills (e.g. defibrillation) being undertaken by a junior clinician, but the 
decision to treat being made by a supervising clinician. This concept would expand the 
provision of prehospital thrombolysis whilst minimizing the education burden of the 
attending clinician and would be suitable for use in remote medical sites such as off shore 
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oil platforms or small remote communities (e.g. Scottish Islands). Such a system is not 
dissimilar to the early use of defibrillation by paramedics where external supervision was 
required before defibrillation was performed. 
5. Protocols, checklists & consent 
5.1 Protocols 
The use of clinicians empowered to make individual thrombolysis decisions removes the 
requirement for fixed protocols, however at the very least an evidence-based clinical 
guidelines for thrombolysis will be required. The availability of a clinical guideline or 
protocol will depend on the level of training provided to the prehospital clinician as 
guidelines support lateral thinking, whereas protocols tend to be more prescriptive.  
The development of the thrombolysis protocol / guidelines needs to incorporate 
adjunctive therapy such as anti-thrombotic agents (e.g. heparin) and anti-platelets agents. 
This is an important aspect of patient care as to date none of the completed prehospital or 
inhospital thrombolysis studies have incorporated optimal anti-platelet and anti-
thrombotic therapy. However, STREAM is currently utilizing the most up-to-date 
thrombolysis strategy. 
5.2 Checklist 
A thrombolysis checklist (Table 1), as part of a protocol / guideline, can support rapid 
decision-making whilst acting as a prompt to steps in the patient’s management. However, 
care must be taken to ensure that the checklist is not overly restrictive as this can lead to 
under treatment of appropriate patients and careful consideration of the checklist layout can 
rapidly identify those patients where prehospital thrombolysis is deemed inappropriate e.g. 
advanced age (Castle et al., 2007a). 
All contra-indications to thrombolysis need to be carefully considered and weighted. Often 
the type and number of contra-indications selected will reflect the risk adverse nature of the 
service delivering prehospital thrombolysis and, therefore, the list of contra-indications may 
change as the prehospital service becomes more established. It is now agreed that previous 
contra-indications such as prior cardiac compressions (Castle et al., 2007b; Cross et al., 1991) 
are no longer barriers to thrombolysis (in fact post cardiac arrest survivors with STEMI 
require urgent reperfusion with either PCI or hrombolysis); nor is diabetic retinopathy. 
(Mahaffey et al., 1997). Furthermore, complete heart block (CHB) is an indicator for rapid 
reperfusion therapy with thrombolysis being an accepted form of treatment as prompt 
reperfusion of the AV node (inferior STEMI with CHB) or intra-ventricular septum/Bundle 
of His (anterior STEMI with CHB) will resolve the arrhythmia thereby removing the need 
for a temporary pacing wire (Castle et al., 2007b) - the very reason typically quoted for with-
holding thrombolytic therapy. All contra-indications to thrombolysis, with the exception of 
myocardial rupture as shown by the LATE Study (1993), are static/not affected by time 
whereas the benefit of thrombolysis is time dependent. Therefore, denying prehospital 
thrombolysis in a patient with STEMI based on one contra-indication only for the patient to 
be transferred to hospital for thrombolytic therapy to be administered will be counter-
productive. 
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 Primary assessment: Can you confirm the following?  Yes  No 
1 
The patient is conscious and coherent, and able to understand that clot 
dissolving drugs will be used? 
  
2 
The patient has symptoms that are characteristic of a heart attack 
(severe, continuous pain in a typical distribution of 15 minutes duration 
or more without remission)? 
  
3 
The symptoms started less than 12 hours ago?
NOTE: Consider “stuttering start” MI – many infarcts start this way. 
  
4 
The pain built up over seconds and minutes rather than starting totally 
abruptly? 
  
5 Breathing does not influence the severity of the pain?   
6 
The systolic blood pressure is more than 80mmHg and less than 
180mmHg and that the diastolic is below 110mmHg despite treatment? 
i.e. Analgesia & GTN for blood pressure and fluid challenge / atropine 
for hypotension). 
  
7 
The electrocardiogram ECG shows abnormal ST elevation of 2mm or 
more in at least 2 standard leads or in at least 2 adjacent precordial leads,
not including V1? 
NOTE: ST elevation can sometimes be normal in V1 and V2. 
  
8 
The QRS width is 0.16 seconds (4 small squares) or less, and that left 
bundle branch block is absent from the tracing? 
NOTE: RBBB is permitted only with qualifying ST elevation. 
LBBB = QRS 140 ms or greater; small narrow R wave in V1 & V2 with 
big S wave; tall upright monophasic R in standard Lead 1 and V6. 
  
 
Secondary assessment (contra-indications): Can you confirm the 
following?
 Yes  No 
9 
The patient is not likely to be pregnant, nor has delivered within the last 
2 weeks? 
  
10 The patient has not had an active peptic ulcer within the last 6 months?   
11 
The patient has not had a stroke of any sort within the last 12 months 
and does not have any permanent disability from a previous stroke? 
  
12 
The patient has no diagnosed bleeding tendency, has had no recent 
blood loss (except normal menstruation) and is not taking warfarin 
(anticoagulant) therapy? 
  
13 
The patient has not had any surgical operation, tooth extractions, 
significant trauma, or head injury within the last 4 weeks? 
  
14 
The patient has not been recently treated for any other serious head or 
brain condition? 
  
15 
The patient is not being treated for liver failure, renal failure, or any 
other severe systemic illness? 
  
Table 1. An example of a thrombolysis checklist 
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5.3 Consent 
It is standard practice to obtain consent from the patient for thrombolytic therapy. The 
complications from thrombolysis are well documented. The patient will need to be 
appraised of the risks in undergoing thrombolysis. A standard statement that is simple, 
clear and concise is used in most established prehospital settings. An example of such a 
statement is as follows (Table 2): 
However, it remains arguable whether a patient in pain or post opiate administration is in a 
position to give informed consent. It, therefore, falls to the attending clinician to ensure that 
they are working in the patient’s best interest. 
Initial Consent 
“It is likely that you are having a heart attack and the best treatment available to you is a 
clot dissolving drug called (specify agent). The quicker you receive this drug, the lower the 
risks of a heart attack-which is why Doctors recommend that the treatment is started as 
soon as possible. These drugs can cause serious side effects in a small minority of patients 
which I can explain to you in more detail if you so wish, but the risks attached to this 
treatment are very much less than the likely benefit. Would you like me to give you the 
injection or would you prefer to have more details?’ 
I hereby consent to the treatment: 
 
________________  _____/_____  ___________________ 
Name of patient   Date / Time  Signature / Thumbprint 
 
In the unlikely event that the patients do want more information they should be given 
the following information: 
 
Further information 
“Treatment at this stage saves the lives of about 1 in every 25 treated. But it can sometimes 
cause serious bleeding. The biggest risk is stroke which affects about 1 patient in every 200 
treated. Some patients also have allergic and other effects that do not usually cause any 
major problems. Would you like me to give you the injection?” 
Table 2. An example of consent 
6. Drugs 
6.1 Thrombolytic agents 
There are a number of thrombolytic agents available, however Tenecteplase (TNK) is the 
only single-use bolus agent available making it the most suitable for prehospital use. 
Despite this, the ideal thrombolytic agent currently does not exist.  
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The characteristics of an “ideal thrombolytic agent” are as follows: 
 Rapid reperfusion (15 - 30 minute) 
 100% efficacy at achieving 100% TIMI 3 in 30 minutes   
 Administered as a single intravenous bolus 
 Lower incidences of intracranial haemorrhage 
 Lower incidences of systemic bleeding and other complications. 
 Specific for recent thrombi 
 Lower incidences for re-occlusion 
 Long-term sustained patency 
 No antigenicity 
 No negative interaction with adjunctive therapy 
 Affordable 
The GUSTO trial (1993) demonstrated the superiority of the accelerated regimen of tissue 
plasminogen activator (tPA, Alteplase) over Streptokinase (STK), however, this came at a 
price of slightly greater risk of intracranial haemorrhage especially in female patients over 
the age of 75 years. However, stroke after thrombolysis is a known risk and in the GUSTO 
trial the stroke rate with STK was 1.19% compared to 1.55% with tPA (Gore et al., 1995). The 
issue of stroke is an important consideration as denying thrombolysis does not decrease the 
stroke rate as STEMI is an independent risk factor for stroke - unrelated to thrombolysis 
primarily due to the higher incidence of atrial fibrillation (AF) and poor left ventricular (LV) 
function caused by STEMI. Therefore, early treatment of STEMI with reperfusion that 
reduces the incidence of AF and LV dysfunction is an important aspect of stroke and 
morbidity reduction. 
Single bolus TNK is now the most widely used thrombolytic agent in the developed world 
partly due to its improved efficacy but also because of ease of administration and variable 
dosing. TNK and Alteplase are equivalent in regard to 30 day mortality, but non-cerebral 
bleeding and blood transfusions are less with TNK.  
The dose of TNK is weight adjusted and administered in a single bolus over 5 seconds as 
compared to 90 minutes of variable rate infusion with tPA or a 30 - 60 minute infusion of 
STK. Although a 30 minute regime for STK exists, it is associated with an increased risk of 
hypotension but by slowing the infusion rate of STK, the incidence of hypotension tends to 
decrease. Reteplase is a more fibrin specific agent administered as a 10 unit twin bolus given 
30 minutes apart. However, the time sensitive nature of the twin bolus administration of 
Reteplase can be problematic. Reteplase is equivalent with reduction in mortality and 
hemorrhage rates achieved with Alteplase.  
The major benefit of the bolus agents lies in the ease of administration and in the simplified 
dosing regimen that reduces the risk of dosing errors. However, the cost of TNK and its 
manufacturer’s recommendation for use up to 6 hours makes the cheaper STK a more 
practical drug of choice for use in the developing world as for each patient treated with 
TNK five patients could be treated with STK (Table 3) (BNF, 2011). Its use as a prehospital 
thrombolytic is worth consideration, particularly in static remote health care settings, 
although its requirement for an infusion plus the incidence of hypotension makes it more 
labour intensive.  
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Streptokinase 
(STK) 
Alteplase 
(tPA) 
Reteplase 
(rtPA) 
Tenecteplase 
(TNK) 
Fibrin selective No Yes Yes Yes 
Plasminogen binding Indirect Direct Direct Direct 
Duration of infusion 
(minutes) 
60 90 10 + 10 
5-10 
seconds 
Half life (minutes) 23 <5 13-16 20 
Fibrinogen breakdown 4+ 1-2+ Not known >tPA 
Early heparin Yes Yes Yes Yes 
Hypotension Yes No No No 
Allergic reactions Yes No No No 
Approximate cost/dose 
£83.44/1.5 
MU 
£600/100 
mg 
£627.27/20 
unit kit 
£502.25/50
mg 
TIMI reflow grade 3 at 90 
min 
32 45-54 60 >tPA 
Recommended use 
Up to 12 
hours 
Up to 12 
hours 
Up to 12 
hours 
Up to 6 hours 
(typically used 
up to 12 hours) 
Table 3. Characteristics of commonly used thrombolytic agents. Adapted from Opie (2009). 
There are two key considerations for the use of STK in the prehospital environment. The 
first is duration of infusion and second the requirement for an expensive infusion pump. 
Although an infusion pump offers better control of drug delivery, this is less of an issue 
with STK as the delivery of STK is less time sensitive when compared to tPA. In static 
medical care environments (e.g. remote medical center) the infusion can be completed 
before hospital transfer as STK can be safely delivered without an infusion pump using 
either a small intravenous bag (100/250ml 0.9% saline) or a pediatric burette supported by 
close clinician supervision. The use of a pediatric burette or a 100/250ml bag of saline is not 
an option for administration during ambulance transfer as the low ceilings in ambulances 
lack the height to ensure fluid flow and this is further aggravated by ambulance movement. 
Novel techniques involving the use of low cost drip counters (that restrict flow through an 
administration set) supported by a pressure infusion bag to maintain a constant pressure 
through the drip counter is feasible but as yet, is unproven. 
The second consideration is the much higher incidence of hypotension and bradycardia. 
This is due to the release of bradykinin and not as commonly thought as an allergic reaction 
(although anaphylaxis is more common with STK, it remains rare). Therefore, the treatment 
of hypotension consists of slowing or stopping the infusion and the administration of a 250-
500ml crystalloid bolus. The routine use of intravenous steroids and anti-histamines offers 
no clinical benefit and in the case of intravenous steroids, it may adversely affect patient 
outcome by affecting myocardial scar tissue formation, thereby potentially increasing the 
risk of myocardial rupture. 
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Streptokinase Tenecteplase 
1.5 mega units over 30-60 minutes (requires 
an infusion pump) 
Single weight adjusted bolus 
Aspirin 300mg Aspirin 300mg 
Clopidogrel age adjusted (75-300mg) Clopidogrel age adjusted (75-300mg) 
No heparin (local policy my vary) 
Weight adjusted heparin bolus followed by 
infusion or weight adjusted subcutaneous 
injection of heparin: 
 
4000 unfractionated heparin bolus 
followed by infusion (an infusion pump is 
mandatory) 
 
Age adjusted enoxaparin. 
Bradycardia (common) reversed by 
atropine 
Bradycardia (less common than STK) 
reversed by atropine 
High risk of drug induced hypotension 
responsive to fluid challenge 
stopping/slowing infusion 
No specific drug induced hypotension 
Labour intensive Not labour intensive 
Affordable (if no infusion pump used) Expensive 
Table 4. Comparison of a STK and TNK treatment regime 
6.2 Adjunctive drug treatment 
6.2.1 Oxygen 
Oxygen is commonly administered during the management of patients during thrombolysis. 
Its routine use in patient with pulse oximetry above 95% has been questioned primarily due to 
the possibility of vasoconstriction and limited evidence of benefit (O'Driscoll, 2008). Oxygen 
remains an important adjunctive therapy in the presence of left ventricular failure although it 
is better provided as part of continuous positive airway pressure. Oxygen should routinely be 
administered  in the presence of arrhythmias (e.g. ventricular tachycardia) (Neumar, 2010), 
hypotension/hypo-perfusion and any post cardiac arrest.  
6.2.2 Analgesia 
Analgesia is a priority therapy in the management of STEMI and intravenous opiates 
(morphine, diamorphine or fentanyl) offer the most effective analgesia although the legal 
framework for administration of these drugs can be problematic resulting in drugs such as 
Tramadol or Nubain being used if legal barriers to opiates do exist. The use of inhaled 
nitrous oxide (Entonox™) remains a useful supplementary analgesic (or primary analgesic if 
prehospital opiates are not available) providing both supplementary oxygen and analgesia 
and the use of Pentrane (common in Australia) is also a useful inhaled analgesic allowing 
higher percentage of inhaled oxygen if required. Thrombolysis also represents effective 
analgesia as the restoration of myocardial blood flow results in pain relief reflecting 
successful reperfusion.  
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Non-pharmacological interventions (re-assurance, calm professional mannerism of the care 
provider) are important aspects of pain relief. The use of rapid road transfer with lights and 
sirens may induce greater patient anxiety (as well as the risk of road traffic collision). If 
prehospital thrombolysis has been administered (with appropriate adjunctive therapy) there 
is little to be gain from rapid transfer to hospital. 
6.2.3 Nitrates 
Although there is no survival benefit to be gained from nitroglycerin it remains a common 
early therapy primarily providing analgesia. Nitroglycerin (0.4mg) is typically administered 
sublingually although intravenous nitrates are also used to manage on-going ischaemic 
chest discomfort, control of hypertension and for the management of pulmonary oedema 
(nitrates are a Class I recommendation for left ventricular failure). Nitrates should not be 
administered to patients who have received phosphodiesterase inhibitor within 24 to 48 
hours and should be administered with care in patients with suspected right ventricular 
infarction as they may induce marked hypotension. Despite this, nitrates are very safe drugs 
for use by prehospital clinicians and it must be remembered that known cardiac patients 
may have already treated themselves with varying doses of nitrates prior to the arrival of 
the prehospital clinician. 
6.2.4 Antiplatelet agents 
Antiplatelets are vital in the management of all acute coronary syndromes (unstable angina, 
non-STEMI and STEMI). Within the context of STEMI management anti-platelet therapy is 
as important as thrombolytic therapy. This is because the intra-coronary thrombus 
responsible for re-infarction tends to be platelet rich and thrombolysis may raise the 
possibility of thrombolytic-induced platelet aggregation (Keeley et al., 2006). 
6.2.4.1 Aspirin 
All patients with suspected acute coronary syndrome (unstable angina, non-STEMI and 
acute STEMI), should be considered for prehospital aspirin treatment as there are relatively 
few contra-indications to a single dose of aspirin (Class I recommendation). Despite this, 
aspirin is often withheld either due to concerns over allergy, adverse drug interactions (e.g. 
Warfarin), confusion due to chronic ongoing use of aspirin or uncertainty of diagnosis. 
Typically unless a patient has a known documented allergic reaction (not just gastric 
irritation) to aspirin or is actively bleeding from a gastrointestinal tract ulcer, aspirin at the 
300mg dose should be given. The choice of 300mg is typically the dose of a single aspirin 
with the administration being initiated as early as possible with consideration being given to 
emergency call takers being empowered to recommend aspirin before the arrival of 
emergency personnel (Class IIb recommendation).  
The benefit of aspirin was established in the ISIS 2 trial (1988) where 162.5 mg aspirin 
resulted in 25 lives saved per 1000 patients primarily by reducing the incidence of re-
infarctions (10 non-fatal re-infarctions per 1000) as well as preventing 3 non-fatal strokes per 
1000 patients. The results from ISIS 2 highlighted that the effectiveness of aspirin alone was 
nearly as effective as STK without aspirin (23% v 25% odds reduction of death) and that by 
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combining aspirin with STK, the magnitude of benefit was highly significant (42% odds 
reduction of death). It is noteworthy that aspirin administration during the ISIS 2 trial was 
anytime within the first 24 hours but a meta-analysis by Freimark et al. (2002) demonstrated 
that early aspirin administration (before thrombolysis) was an independent factor in patient 
survival at 1 year (5% vs 11% survived with early aspirin; odds ratio 0.41; 95% CI 0.21-0.74). 
The benefits of aspirin for acute STEMI are attributed to its inhibition cyclo-oxygenase 
dependent platelet activation. The administration of an initial dose of 160-300mg aspirin 
ideally non-enteric coated formulation chewed is a Class I recommendation for acute 
STEMI. Intravenous or rectal aspirin are also acceptable routes of administration.  
Although over-treatment of patients or the administration of an unnecessary treatment 
cannot be endorsed, the benefits of early use of aspirin in any patient with symptoms 
suspected of a STEMI (or other acute coronary syndrome) is such that the potential of over-
treatment of patients is arguably worth the risk, especially when comparing the maximum 
acute anti-platelet dose of aspirin (300mg) to the analgesic dose of aspirin of 600-900mg. 
6.2.4.2 Clopidogrel 
Clopidogrel is a potent platelet inhibitor and the anti-platelet benefits of clopidogrel in 
combination with aspirin is to reduce ischaemic events in non ST-elevation acute coronary 
syndromes (Yusuf et al., 2001) and in patients undergoing percutaneous coronary 
intervention - PCI CLARITY (2005). The COMMIT-CCS 2 (2005) trial involving more than 45 
000 patients (many post thrombolysis) demonstrated that administration of Clopidogrel 
(75mg daily) with aspirin and standard treatment safely reduced mortality and major 
vascular events. In the CLARITY-TIMI 28 Trial (2006), patients 75 years and younger with 
acute STEMI received thrombolysis supported by a loading dose of 00mg Clopidogrel 
followed by 75mg once daily and either low molecular weight heparin (LMWH) or 
unfractionated heparin (UFH). The combination of dual anti-platelet therapy 
(aspirin/clopidogrel) with thrombolytic treatment demonstrated more favorable 
angiographic patency of the infarct related artery and a reduction in mortality. A major 
contributor to mortality reduction was the reduction in the re-infarction rate in those 
patients receiving dual anti-platelet therapy. This was without an associated increase in the 
rate of bleeding.  
The importance of improved patency and lower incidence of re-infarction was confirmed in 
the ECG CLARITY-TIMI 28 Study (2006) where the use of clopidogrel was shown to 
improve late coronary patency and clinical outcomes in those patients who achieve ST-
segment resolution by preventing re-occlusion of open arteries rather than by facilitating 
early reperfusion. The administration of 300mg loading dose of clopidogrel in association 
with thrombolysis to patients less than 75 years of age is a Class IIa recommendation and it 
is common practice to adjust the dose in the over 75  year old patients to 75mg based on the 
COMMIT data. 
Newer oral antiplatelets such Prasugrel and Ticagrelor are now available with potentially 
improved antiplatelet as Ticagrelor produces a more profound and consistent antiplatelet 
effect than clopidogrel (Wallentin et al., 2003), but as yet to be studied in conjunction with 
thrombolytic therapy.  
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6.2.5 Anticoagulants 
Heparin is considered to be effective and is routinely given as an adjunct for PCI and 
thrombolytic therapy although it is commonly withheld in the first 24 hours in those 
patients receiving STK. The role of heparin is primarily to reduce re-infarction but the 
combination of dual anti-platelet therapy, thrombolysis and heparin may increase the risk of 
bleeding. The American Heart Association guidelines call for careful weight based dosing of 
heparin with thrombolytic therapy in STEMI (Antman et al., 2008). 
The timing of heparin therapy when using fibrin specific thrombolytic agents (tPA, reteplase 
and TNK) is an important aspect of patient management. In an observational study of the 
United Kingdom (UK) national registry the frequency of re-infarction during hospital 
admission after thrombolytic treatment of 35, 356 STEMI patients during 2005–2006 was 
analyzed. Re-infarction rates with inhospital treatment were similar for reteplase (6.5%) and 
TNK (6.4%) but were higher for those patients treated by paramedics in the community. 
When the interval from prehospital treatment to hospital arrival was greater than 30 
minutes re-infarction rates were 12.5% for reteplase, and 11.4% for TNK. For intervals 
shorter than 30 minutes the re-infarction rates were significantly greater for TNK (9.3% than 
reteplase (4.2%). Overall, re-infarction rates were higher after prehospital treatment with 
TNK than reteplase (9.6% vs 6.6%, p=0.005).  
The differences in re-infarction rates were considered to be primarily due to the different 
uses of adjunctive anti-thrombotic therapy as UK paramedic thrombolysis protocols only 
allowed a single bolus dose of heparin prior to thrombolysis but did not allow for ongoing 
heparinization until arrival inhospital as compared to inhospital practice which resulted in 
either an infusion of UFH (800-1000 IU per hour adjusted to aPTT) or weight adjusted 
LMWH. It was also noted that on arrival at hospital there was often a delay in the 
commencement of heparin therapy, either due to confusion about the prehospital protocol 
or other time related pressures. In addition, clopidogrel was commonly administered early 
in association with inhospital thrombolysis but only after arrival at hospital for those 
patients receiving prehospital thrombolysis (Horne et al., 2009). This may also have been a 
confounding factor as Keeley (2006) noted that thrombolysis induced platelet aggregation 
was a possible cause of re-infarction following thrombolysis. 
UFH has long been regarded as the anti-thrombotic agent of choice in the adjunctive 
treatment of patients with STEMI until the introduction of enoxaparin. The ASSENT-3 PLUS 
Trial (2003) evaluated the feasibility, efficacy and safety of prehospital enoxaparin or UFH 
with tenecteplase. There was a reduction in the composite of 30 day mortality, inhospital re-
infarction or inhospital refractory ischemia in the enoxaparin group (14.2% vs 17.4%., p = 
0.08). However, there was a tendency towards higher rates of intracranial haemorrhage 
(ICH) and major bleeding in the enoxaparin group. The risk for ICH and major bleeding was 
mainly confined to patients > patients over 75 years. It must be noted that in ASSENT-3 
PLUS, the dose of enoxaparin was not weight adjusted. The safety concern of enoxaparin 
among elderly patients was addressed by the ExTRACT-TIMI-25 Trial (2005) that 
randomized more than 20 000 thrombolysed patients to receive either enoxaparin or UFH. 
The ExTRACT-TIMI 25 study was significantly changed from the ASSENT 3 study with 
patients > to greater than 75 years of age not receiving the IV bolus of enoxaparin as well as 
receiving a reduced dose of subcutaneous enoxaparin (75%)  with a maximum ceiling dose 
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of subcutaneous enoxaparin for the patients under 75 being set at 100mg and 75mg for the 
over 75 age group. The primary endpoint of this study was all cause mortality or non-fatal 
reinfarction at 30 days. Treatment with enoxaparin was found to be superior to UFH but 
was associated with an increase with major bleeding episodes. A telephone follow up at 1 
year showed a sustained reduction in mortality or re-infarction when using the enoxaparin 
strategy (Morrow et al., 2010). Data from a meta-analysis from 12 earlier trials involving 
more than 49 000 patients support these results (Murphy et al., 2007). Enoxaparin is 
administered as an initial dose of 30mg intravenous bolus, followed by 1mg/kg 
subcutaneously within 15 minutes and is a Class I recommendation. 
The likely reason for both the reduction in re-infarctions but also the increased risk of 
bleeding associated with enoxaparin is that enoxaparin (in fact all LMWHs) provide more 
predictable anticoagulation. Whereas UFH is both dose and person sensitive typically 
requiring frequent dose changes as dictated by aPTT and commonly results in either under 
or over anti-coagulation. 
Enoxaparin offers a number of operational benefits for use with prehospital thrombolysis; 
primarily the absence of an infusion pump that is required when administering an infusion 
of UFH. Two single 100mg dose syringes of enoxaparin is adequate to support prehospital 
thrombolysis with one syringe being used for the 30mg IV dose followed by subsequent 
subcutaneous dose (the maximum subcutaneous dose of enoxaparin remains 100mg). The 
intravenous dose of enoxaparin can be simply administered by decanting all of a 100mg 
dose of enoxaparin into a 10ml syringe and then diluting with water for injection to a total 
volume of 10mls thereby providing 10mg enoxaparin per ml. A multiple use vial of 
enoxaparin for IV administration is also available. 
6.2.6 Steroids and antihistamines 
The routine administration of steroids and antihistamines to prevent 
hypotension/bradycardia especially in association with Streptokinase complicates the 
administration process and is unlikely to prevent hypotension as the cause of Streptokinase 
induced  hypotension is primarily due to speed of administration (Lew et al., 1985; Tatu-
Chiţoiu et al., 2004) and the action of bradykinin activated by Streptokinase (Hoffmeister et 
al., 1998).  
Tatu-Chiţoiu et al (2004) noted that the incidences of hypotension occurred in nearly half of 
all patients treated with Streptokinase but it did not adversely affect patient outcome 
whereas the prophylactic use if steroids is linked with an increased risk of myocardial 
rupture (Mannisi et al., 1987) and is not recommended by the leading international 
cardiology societies (Van de Werf et al., 2008). 
7. Support systems 
Studies have clearly demonstrated that thrombolytic therapy can be safely administered in 
the prehospital environment by doctors, paramedics and nurses. The most effective system 
will depend on population demographics, geographical factors, the structure and financial 
resources of the emergency medical services. Regardless of who undertakes thrombolysis, 
the personnel need to be capable of rapid diagnosis, early risk stratification, minimal 
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treatment delay and rapid administration of a thrombolytic agent. EMS systems vary 
throughout the world. In 75% of Europe thrombolysis is undertaken by emergency 
physicians while in many other settings like United Kingdom, Australia and United States 
of America, it is undertaken by paramedics. In most countries, the use of non-doctors in the 
prehospital environment seems to be the most practical and cost effective option. 
The practice of paramedic thrombolysis may be undertaken independently or under direct 
supervision depending on the local emergency medical system. A system of consultation 
and 12-lead ECG transmission with CCU nurses/a senior paramedic/specialist clinician 
experienced in STEMI management is highly recommended at the initial implementation of 
thrombolysis and for on-going clinical support in difficult cases (Liem et al., 2007; McLean et 
al., 2008). Furthermore, paramedics can also fast track acute STEMI patients to CCU by by-
passing the emergency department as well as by-passing local hospitals to deliver the 
patient to a hospital with an on-site catheter laboratory for either rescue angioplasty or pre-
discharge angioplasty. These strategies have demonstrated reductions in door-to-balloon 
time and mortality (Afolabi et al., 2007; Bång et al., 2008; Le May et al., 2006).  
The transmission of 12-lead ECG may be challenging and is dependent of the use of cellular 
technology which may result in the inability to transmit the ECG due to poor coverage or 
drop zones. The transmission of the ECG may involve the pairing of cellular phones and 
ECG machines therefore will need to be tested and practiced to prevent user error. 
8. Quality assurance 
An on-going continuous professional development programme which incorporates quality 
improvement measures obtained by on-going monitoring of prehospital thrombolysis via 
clinical audit and feedback should be mandatory for continued safe prehospital 
thrombolysis and staff development. A clinical review team incorporating all role players 
would need to meet regularly to appraise all cases of prehospital thrombolysis. In settings 
where the frequency of the performance of thrombolysis is low, an on-going programme of 
refresher training is essential to maintain skill competence. External surveillance registries 
like MINAP and the Swiss registries provide valuable information on trends in management 
of acute STEMI and should be used to guide treatment timeframes and clinical outcomes.  
9. Other uses for prehospital thrombolysis 
Prehospital thrombolysis is primarily aimed at the treatment of patients with symptoms and 
ECG diagnosis of STEMI. Although this will remain the mainstay of the use of thrombolytic 
therapy, thrombolysis is also used in the treatment of other clinical emergencies. 
9.1 Stroke 
Although stroke thrombolysis is not suitable for initiation in the community due to the need 
for a CT scan and in a small subset of patients an MRI, the early identification of patients 
with a possible stroke is vital. This has required a change in emphasis within emergency 
departments and ambulance services where an acute stroke has now been identified as a 
time-sensitive clinical emergency. The UK has just completed a mass TV awareness 
campaign for the recognition of stroke, building on the brain attack model developed in 
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America. Prehospital clinicians are, therefore, pivotal in the early identification of suspected 
stroke patients typically using the Fast, Arm, Speech, Test (FAST) supported by pre-arrival 
alerts to hospitals equipped to deliver stroke thrombolysis (with 3-4 hours of onset of 
symptoms). 
9.2 Cardiopulmonary resuscitation (CPR) 
The use of thrombolysis during resuscitation is also a potential treatment option but the 
routine administration of thrombolysis during cardiac arrest management is not endorsed 
(Class III recommendation). However, its use to treat a confirmed or suspected massive 
pulmonary embolism or STEMI should be considered on a case-per-case bases (Class IIa 
recommendation) (Neumar, 2010). Confirmation of diagnosis remains challenging but is 
primarily based on clinical history supported by clinical suspicion although the use of 
bedside ECHO for the diagnosis of massive pulmonary embolism is worth consideration 
(typically to look at the right ventricle) but the expertise for this is limited in the prehospital 
environment. 
Following the administration of thrombolytic therapy, during CPR, the period of 
resuscitation should be extended to a minimum of 60 minutes (Neumar, 2010) and this 
protracted period of resuscitation is an important consideration when initiating 
thrombolytic therapy. The administration of thrombolysis during resuscitation does not 
replace the need for effective compressions and supportive ventilation but represents a 
targeted treatment for a small subset of patients. 
10. Conclusion 
Prehospital thrombolysis offers two unique clinical pathways for the patient presenting with 
STEMI. Prehospital thrombolysis can be the preferred reperfusion strategy in developing 
countries or countries without rapid access to primary angioplasty facilities or can provide 
ultra-early reperfusion as part of a hybrid reperfusion service. Key to the success of any 
prehospital service is the recruitment and training of appropriately qualified personnel 
although in remote areas the use of telemedicine and electronic data transmission can 
support the administration of thrombolysis by junior clinicians. Although thrombolysis 
offers significant patient benefits, it needs to be appropriately delivered and supported by 
adjunctive therapy which should include dual anti-platelet therapy for all patients 
supported by heparin (ideally LMWH) as appropriate.  
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